Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Lenalidomide Plus Rituximab Represents Acceptable Chemo-Free Alternative for Untreated Advanced Follicular Lymphoma

August 18th 2022

The combination of lenalidomide and rituximab demonstrated durable safety and efficacy that was comparable to that achieved with rituximab plus chemotherapy in previously untreated patients with follicular lymphoma, according to 6-year data from the phase 3 RELEVANCE trial.

Treating Patients With Immune Thrombocytopenia in the Era of COVID-19

August 18th 2022

A brief review of how the management of patients with immune thrombocytopenia has been impacted by the COVID-19 pandemic.

Anbalcabtagene Autoleucel Shows Promise in Relapsed/Refractory LBCL

August 17th 2022

Won Seog Kim, MD, PhD, discusses the potential clinical role of Anbalcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma and the continued evolution of CAR T-cell therapy.

Subcutaneous Epcoritamab Plus R-DHAX/C Shows Promising Preliminary Activity in ASCT-Eligible, R/R DLBCL

August 15th 2022

Raul Cordoba, MD, PhD, discussed the efficacy and safety findings from cohort 4 of the EPCORE NHL-2 trial, the benefits observed with epcoritamab monotherapy in patients who did not proceed to transplant, and what the addition of epcoritamab to R-DHAX/C could mean for patients with relapsed/refractory DLBCL.

Teclistamab Demonstrates Durable Response Rates in BCMA-Pretreated Multiple Myeloma

August 15th 2022

Saad Z. Usmani, MD, MBA, FACP, discusses key efficacy findings that support the use of teclistamab in patients with relapsed/refractory multiple myeloma who have had prior exposure to BCMA-targeted agents.

Steroid-Refractory Chronic GVHD: Selecting and Sequencing Therapy

August 15th 2022

Following their review of available treatment for steroid refractory chronic GVHD, experts consider how they would optimally select and sequence therapy.

Treatment Armamentarium for Steroid-Refractory Chronic GVHD

August 15th 2022

Comprehensive discussion on each of the 3 standard-of-care treatment options for patients with steroid refractory chronic GVHD.

Tolinapant Displays Encouraging Activity and Safety in Relapsed/Refractory PTCL/CTCL

August 11th 2022

Single-agent tolinapant generated promising response rates with a manageable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma, according to data from the phase 2 ASTX660-01 trial.

CC-99282 Demonstrates Manageable Safety Profile, Elicits Favorable Responses in Non-Hodgkin Lymphoma

August 11th 2022

Jean-Marie Michot, MD, discusses the methods and rationale for the CC-99282-NHL-001 study.

How Does Treatment Duration Impact Outcomes in ITP?

August 11th 2022

Experts consider how treatment duration can impact patient outcomes in immune thrombocytopenia and discuss discontinuation of TPO-Ras.

Risk of Thrombosis With TPO-RAs in Immune Thrombocytopenia

August 11th 2022

Comprehensive discussion on nuancing the risk of thrombosis with thrombopoietin receptor agonists in immune thrombocytopenia.

Leukemia Experts Reflect on Defining Moments as Women in the Field

August 8th 2022

Drs Luger, Roboz, and Stock discuss the issues that were most prominent in leukemia treatment when they began their careers and what motivated them to continue to work toward progress in the field even when treatment outcomes were dismal. They also share their experiences with being women in their chosen career paths, such as how their gender has influenced their professional and personal decisions, as well as how they interact with and support other female colleagues.

Management and Work-up of Patients for Salvage Therapy

August 8th 2022

The panelists share their approach to the treatment and work-up of patients who require salvage therapy.

Frontline Treatment Strategies for Chronic GVHD

August 8th 2022

An overview of the frontline treatment armamentarium for patients diagnosed with chronic graft versus host disease.

Improving the Early Identification of Chronic Graft Versus Host Disease

August 8th 2022

Shifting their focus to chronic graft versus host disease, panelists emphasize the importance of early identification and diagnosis.

Strategies for Supportive Care and Monitoring in Patients Who Have Received CAR T-Cell Therapy

August 8th 2022

Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.

Bispecific Antibodies Represent Appealing Option for Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma

August 5th 2022

Amrita Krishnan, MD, discusses emerging data on bispecific antibodies, the exploration of the antibody-drug conjugate belantamab mafodotin, and the challenges of delivering CAR T-cell therapy in the right setting to the appropriate patients with multiple myeloma.

Dr. Tilly on Pola-R-CHP in an Asia Subpopulation of Patients With DLBCL

August 5th 2022

Hervé Tilly, MD, PhD, discusses the efficacy of polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone in an Asia subpopulation of patients with diffuse large B-cell lymphoma.

Dr. Maude on Safety of Tisagenlecleucel in Pediatric B-ALL

August 5th 2022

Shannon L. Maude, MD, PhD, discusses notable long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.

New Acalabrutinib Tablet Formulation Approved for Current Indications, Including CLL, SLL, and MCL

August 5th 2022

The FDA has approved a new tablet formulation of acalabrutinib for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and for those with relapsed or refractory mantle cell lymphoma.